By: Tim Cortese From: cancernetwork.com The ProSense® cryoablation system achieved the highest complete ablation rate compared with alternatives, with 95% of patients with breast cancer being “very satisfied” or “satisfied” with the thermal ablation, according to a press release from the developer, IceCure Medical.1 The results came from the phase 2 THERMAC trial, which compared radiofrequency ablation, microwave ablation, and …
Study Using IceCure’s ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
Provided by: IceCure Medical From: prnewswire.com IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced new data from a preliminary, independent breast cancer study conducted by Principal Investigator and ProSense® user, Dr. Federica. di Naro, of Azienda …
IceCure Medical Receives FDA Response to De Novo Classification Request for Breast Cancer
By: Ice Cure Medical From: prnewswire.com IceCure Medical Ltd. (Nasdaq: ICCM), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that the U.S. Food and Drug Administration (“FDA”) has at this time denied the Company’s De Novo Classification request for breast cancer which was submitted based …
Cryoablation Technology for Early Breast Cancer Earns Breakthrough Therapy Designation
By: Audrey Sternberg From: cancernetwork.com The next-generation cryoablation technology ProSense was granted breakthrough device designation to treat certain patients with T1 breast tumors. Breakthrough device designation was granted to the next-generation cryoablation technology ProSense for use in patients with T1 invasive breast cancer as well as in patients not suitable for surgical alternatives for the treatment of their tumors, reported IceCure …
Thailand, with a Population of 70 million People, Joins Other Significant Territories Japan and Singapore That will Benefit From IceCure’s Cryoablation Products
From: PR Newswire IceCure Medical Ltd. (TASE: ICCM), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today announced that it has expanded its strategic partnership with Terumo Corporation (Tokyo: 4543, TRUMY:OTC US), a leading Japanese medical devices company with a global footprint.. The expanded partnership reflects the ongoing success of the …
IceCure Receives FDA Clearance for Expanded Indications of Cryoablation Technology and Regulatory Approval of New MultiSense System
Plans to Increase U.S. Presence and Operations Expands Use of Cryoablation Technology to Treat Liver and Kidney Tumors Following the additional U.S. Food and Drug Administration (FDA) clearance for its Cryoablation Technology, IceCure Medical Ltd. (TASE: ICCM), an Israeli medical device company, developers of a non-surgical Liquid Nitrogen (LN2) cryoablation technology to destroy benign and cancerous tumors by freezing, plans …